Insurer Seeks To Recover ‘Illegal’ Daraprim Overcharges Due To Obstruction Of Generics
Proposed class action lawsuit by Blue Cross Blue Shield of Minnesota against Vyera Pharmaceuticals could set a precedent for other health insurer actions against manufacturers.
You may also be interested in...
White House, Democrat majority in Congress and likely next FTC chair support the agency wielding the authority, says advertising law attorney Holly Melton. Supreme Court, though, likely will rule in pending cases that a strict reading of an FTC regulation doesn’t grant monetary penalty authority.
In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.
Results from the US Food and Drug Administration’s RCT DUPLICATE demonstration are in. The findings both legitimize certain real-world evidence studies and also highlight the challenges involved in using RWE to replicate randomized clinical trials.